Viemed Healthcare Inc (VMD) (Q3 2026) Earnings Call Highlights: Record Revenue

Viemed Healthcare reported Q3 2026 record revenue of $80M. CEO Casey Boyd discussed state rollout timelines, expecting gradual growth. CFO Trey Fitzgerald addressed sequential growth gaps, seasonal trends, and financial KPIs, targeting EBITDA above 20%. Accounts receivable delays impacted cash flow but are expected to resolve in Q4. Boyd also updated on sales force training, M&A pipeline, and patient education progress.

Original reporting
Published Nov 5, 2026, 11:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 11:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Viemed Healthcare Inc (VMD) (Q3 2026) Earnings Call Highlights: Record Revenue — source image
Decision brief

The 30-second read

$VMDBullishMed
01

Why it matters

Management's comments on margin targets and AR resolution suggest operational improvements, but cash conversion remains a risk.

02

Market read

Earnings call provides fresh guidance for a micro‑cap health‑tech stock, offering limited but actionable insight for traders.

03

What to watch

Potential regulatory changes in maternal health reimbursement and competitive pressure from larger health‑tech firms.

Relevance 7/10Novelty 7/10Timing: post‑earnings Q3 2026 release

Background

Viemed Healthcare provides home‑based respiratory and maternal health services; the Q3 2026 call covered operational metrics and future growth plans.

Company-level read

Ticker impact

$VMDBullishMedium confidence
Context

Q3 2026 earnings call disclosed record revenue, free cash flow of $26‑27M, AR $35M and guidance on growth and margins.

Expected impact

potential modest upside as investors price in continued revenue growth and margin expansion

Evidence & confidence

Guidance is positive but not extraordinary; market may react positively but limited by company size.

Market effects

Signals continued demand in home‑based respiratory and maternal health services, modestly supportive for the broader health‑tech sector.

Limited to U.S. healthcare investors; no broader regional effect.

Low global relevance; primarily a micro‑cap US health‑tech story.

Counterpoint

Guidance may be overly optimistic given rising AR and cash conversion delays; stock could face pressure if cash flow does not improve.

Key entities

  • Casey Boyd

    CEO of Viemed Healthcare

  • Trey Fitzgerald

    CFO of Viemed Healthcare

Related articles

$VMDMedAI 8/10

Viemed Healthcare Q3 Earnings Call Highlights

VieMed Healthcare (VMD) reported Q3 operating cash flow of $11.5M and free cash flow of $4M. The company expects Q4 improvements in collections and active ventilator patients. Full-year revenue guidance was raised to $316M-$320M, while adjusted EBITDA was narrowed to $64M-$66M. VieMed had $9.7M in cash and $5.3M in borrowings at Q3's end, with a $1M share buyback and $2M term-loan repayment in October.

$VMDMed

VIEMED HEALTHCARE ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS

VIEMED HEALTHCARE, INC. (VMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. VIEMED HEALTHCARE ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS Lafayette, Louisiana (November 4, 2026) Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and chronic disease management, an

$VMDMedAI 8/10

Viemed Healthcare Targets Low-20% Growth as Home Ventilation Opportunity Expands

Viemed Healthcare (NASDAQ: VMD) anticipates low-20% revenue growth in 2026, with projected revenue of $317M and EBITDA of $66M. The company's ventilator business averages $1,050 monthly per rental, with an average patient length of 17 months. Viemed has expanded into sleep therapy, maternal health, and other areas, completing three acquisitions in the past three years. The company has no net debt and has repurchased nearly 700,000 shares. Management sees organic growth and strategic acquisitions

Med

Viemed Healthcare Announces New Share Repurchase Program of Up to 5% of Shares Outstanding – Minichart

Viemed Healthcare reported Q2 2026 revenue of $78.1M (up 24% Y-o-Y) and Adjusted EBITDA of $13.7M. The company announced a new share repurchase program for up to 5% of outstanding shares, following a strong first half with 680,802 shares repurchased. Full-year 2026 guidance is $314M-$320M in revenue and $64M-$68M in Adjusted EBITDA. The company has a strong balance sheet with $10.7M in cash and no net debt as of June 30, 2026.